Single-use bioreactors market is estimated to attain a CAGR of 20.2% through 2027 owing to various advantages such as reduced cross contamination, cost-effectiveness, flexibility and increased productivity.

This pipeline analysis focuses on Immune Checkpoint therapeutics.